Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Ji L, Gao L, Xue H, Tian J, Wang K, Jiang H, Huang C, Lian Q, Yuan M, Gao G, Lu Y, Han J, Fu W, Wang H, Zhang Y, Shi X, Wen B, Shi B, Hu W, Guo T, Xing Y, Li Y, Li Q, Zheng Q, Yang M, Ning J, Guo M, Li Y, Pan H.
Ji L, et al. Among authors: guo t.
Lancet Diabetes Endocrinol. 2025 Jun 20:S2213-8587(25)00141-X. doi: 10.1016/S2213-8587(25)00141-X. Online ahead of print.
Lancet Diabetes Endocrinol. 2025.
PMID: 40555243